CMS and FDA Announce RAPID Coverage Pathway to Accelerate Patient Access to Life-Changing Medical Devices
The FDA and CMS have announced the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway, which aims to accelerate Medicare access for specific FDA-designated Class II and Class III Breakthrough Devices.
Manufacturers of Class II and Class III medical devices that have received Breakthrough Device designation, as well as regulatory and market access teams managing Medicare reimbursement strategies.
The RAPID pathway suggests a significant shift toward closer coordination between regulatory clearance/approval and national coverage determination. This alignment could reduce the 'gap' between FDA authorization and patient access, potentially requiring companies to integrate reimbursement planning much earlier in the clinical development and regulatory submission cycles. Regulatory professionals should note that while the source focuses on Medicare populations, such pathways often set precedents for commercial payer behavior.
1. Review current and upcoming Class II/III pipelines to identify candidates for Breakthrough Device designation. 2. Cross-functional teams should monitor for detailed eligibility criteria and enrollment procedures as they are released. 3. Assess internal readiness to synchronize regulatory submission timelines with reimbursement documentation requirements.
CMS and FDA announce the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway, a new pathway designed to expedite access to certain FDA-designated Class II and Class III Breakthrough Devices for people with Medicare.
Open in openFDA / FDA.gov